Evidence Tables and Quality Ratings

Roger Chou; Daniel Hartung; Basmah Rahman; Ngoc Wasson; Erika Cottrell; Rongwei Fu

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Chou R, Hartung D, Rahman B, et al. Treatment for Hepatitis C Virus Infection in Adults [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Nov. (Comparative Effectiveness Reviews, No. 76.)

Appendix HEvidence Tables and Quality Ratings

Key Questions 2a - 3b

Evidence Table 1. Trials of dual therapy with pegylated interferon alpha-2a plus ribavirin compared with pegylated interferon alfa-2b plus ribavirin (MS Word, 65K)

Evidence Table 2. Quality rating: Trials of dual therapy with pegylated interferon alpha-2a plus ribavirin compared with pegylated interferon alfa-2b plus ribavirin (MS Word, 32K)

Evidence Table 3. Trials of protease inhibitors plus pegylated interferon and ribavirin (MS Word, 57K)

Evidence Table 4. Quality rating: Trials of protease inhibitors plus pegylated interferon and ribavirin (MS Word, 33K)

Evidence Table 5. Trials of dual therapy with pegylated interferon plus ribavirin: duration effects (MS Word, 100K)

Evidence Table 6. Quality rating: Trials of dual therapy with pegylated interferon plus ribavirin: duration effects (MS Word, 35K)

Evidence Table 7. Trials of dual therapy with pegylated interferon plus ribavirin: dose effects (MS Word, 78K)

Evidence Table 8. Quality rating: Trials of dual therapy with pegylated interferon plus ribavirin: dose effects (MS Word, 33K)

Key Question 4

Evidence Table 9. Studies on sustained virologic response and clinical outcomes (MS Word, 56K)

Evidence Table 10. Quality rating: Studies on sustained virologic response and clinical outcomes (MS Word, 34K)

Evidence Table 11. Sustained virologic response and clinical outcomes summary results (MS Word, 36K)

Evidence Table 12. Studies on sustained virologic response and quality of life (MS Word, 43K)

Evidence Table 13. Quality rating: Studies on sustained virologic response and quality of life (MS Word, 33K)

Evidence Table 14. Sustained virologic response and quality of life summary table scores (MS Word, 35K)

Appendix H References

1.: Ascione A, De Luca M, Tartaglione MT, et al. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection. Gastroenterol. 2010 Jan;138(1):116–22. [PubMed: 19852964]
2.: Bruno R, Sacchi P, Ciappina V, et al. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study. Antiver Ther. 2004;9(4):491–7. [PubMed: 15456079]
3.: Di Bisceglie AM, Ghalib RH, Hamzeh FM, et al. Early virologic response after peginterferon alpha-2a plus ribavirin or peginterferon alpha-2b plus ribavirin treatment in patients with chronic hepatitis C. J Viral Hepat. 2007 Oct;14(10):721–9. [PubMed: 17875007]
4.: Escudero A, Rodriguez F, Serra MA, et al. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study. J Gastroenterol Hepatol. 2008 Jun;23(6):861–6. [PubMed: 18422960]
5.: Kamal SM, Ahmed A, Mahmoud S, et al. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis. Liver Int. 2011;31(3):401–11. [PubMed: 21281434]
6.: Khan A, Awan A, Shahbuddin S, et al. Abstract # S1231: Peginterferon alfa 2a/ribavirin versus peginterferon alfa 2b/ribavirin combination therapy in chronic hepatitis C genotype 3. Gastroenterol. 2007;132(4):A200.
7.: Mach TH, Ciesla A, Warunek W, et al. Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b. Polskie Archiwum Medycyny Wewnetrznej. 2011;121(12):434–40. [PubMed: 22157768]
8.: Magni CNF, Argenteri B, Giorgi R, Mainini A, Pastecchia C, Ricci E, Schiavini M, Terzi R, Vivirito MC, Resta M. Abstract #883: Antiviral activity and tolerability between pegylated interferon alpha 2a and alpha 2b in naive patients with chronic hepatitis C: Results of a prospective monocentric randomized trial. Hepatology. 2009;50(S4):720A.
9.: McHutchison J, Sulkowski M. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C. J Viral Hepat. 2008;15(7):475–81. [PubMed: 18363672]
10.: Miyase S, Haraoka K, Ouchida Y, et al. Randomized trial of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin for chronic hepatitis C in Japanese patients. J Gastroenterol. 2012:1–8. [PubMed: 22382633]
11.: Rumi MG, Aghemo A, Prati GM, et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterol. 2010 Jan;138(1):108–15. [PubMed: 19766645]
12.: Silva M, Poo JL, Wagner F, et al. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). J Hepatol. 2006;45(2):204–13. [PubMed: 16780997]
13.: Yenice N, Mehtap O, Gumrah M, et al. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients. Turk J Gastroenterol. 2006 Jun;17(2):94–8. [PubMed: 16830289]
14.: Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009 Apr 30;360(18):1839–50. [PubMed: 19403903]
15.: Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405–16. [PubMed: 21696307]
16.: Kumada H, Toyota J, Okanoue T, et al. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol. 2012;56(1):78–84. [PubMed: 21827730]
17.: Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010 Aug 28;376(9742):705–16. [Erratum appears in Lancet. 2010 Oct 9;376(9748):1224 Note: SPRINT-1 investigators [added]; multiple investigator names added] [PubMed: 20692693]
18.: Marcellin P, Forns X, Goeser T, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterol. 2011 Feb;140(2):459–68.e1. quiz e14. [PubMed: 21034744]
19.: McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360(18):1827–38. [PubMed: 19403902]
20.: Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011 Mar 31;364(13):1195–206. [PMC free article: PMC3766849] [PubMed: 21449783]
21.: Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365(11):1014–24. [PMC free article: PMC3809077] [PubMed: 21916639]
22.: Andriulli A, Cursaro C, Cozzolongo R, et al. Early discontinuation of ribavirin in HCV-2 and HCV-3 patients responding to Peg-interferon alpha-2a and ribavirin. J Viral Hepat. 2009 Jan;16(1):28–35. [PubMed: 18761603]
23.: Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology. 2006 Apr;130(4):1086–97. [PubMed: 16618403]
24.: Berg T, Weich V, Teuber G, et al. Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients. Hepatology. 2009 Aug;50(2):369–77. [PubMed: 19575366]
25.: Brandao C, Barone A, Carrilho F, et al. The results of a randomized trial looking at 24 weeks vs 48 weeks of treatment with peginterferon alpha-2a (40 kDa) and ribavirin combination therapy in patients with chronic hepatitis C genotype 1. J Viral Hepat. 2006 Aug;13(8):552–9. [PubMed: 16901286]
26.: Buti M, Lurie Y, Zakharova NG, et al. Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Hepatology. 2010 Oct;52(4):1201–7. [PubMed: 20683847]
27.: Dalgard O, Bjoro K, Ring-Larsen H, et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology. 2008 Jan;47(1):35–42. [PubMed: 17975791]
28.: Ferenci P, Laferl H, Scherzer T-M, et al. Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response. Gastroenterol. 2010 Feb;138(2):503–12. [Reprint in Korean J Hepatol. 2010 Jun;16(2):201–5; PMID: 20606507] [PubMed: 19909752]
29.: Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004 Mar 2;140(5):346–55. [PubMed: 14996676]
30.: Ide T, Hino T, Ogata K, et al. A randomized study of extended treatment with peginterferon alpha-2b plus ribavirin based on time to HCV RNA negative-status in patients with genotype 1b chronic hepatitis C. Am J Gastroenterol. 2009 Jan;104(1):70–5. [PubMed: 19098852]
31.: Kamal SM, El Tawil AA, Nakano T, et al. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut. 2005 Jun;54(6):858–66. [PMC free article: PMC1774522] [PubMed: 15888797]
32.: Lagging M, Langeland N, Pedersen C, et al. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology. 2008 Jun;47(6):1837–45. [PubMed: 18454508]
33.: Lam KD, Trinh HN, Do ST, et al. Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6. Hepatology. 2010 Nov;52(5):1573–80. [PubMed: 21038410]
34.: Liu C-H, Liu C-J, Lin C-L, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis. 2008 Nov 15;47(10):1260–9. [PubMed: 18834319]
35.: Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2005 Jun 23;352(25):2609–17. [PubMed: 15972867]
36.: Manns M, Zeuzem S, Sood A, et al. Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C. J Hepatol. 2011;55(3):554–63. [PubMed: 21237227]
37.: Mecenate F, Pellicelli AM, Barbaro G, et al. Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial. BMC Gastroenterol. 2010;10:21. [PMC free article: PMC2837223] [PubMed: 20170514]
38.: Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. Hepatology. 2007 Dec;46(6):1688–94. [PubMed: 18046717]
39.: Sanchez-Tapias JM, Diago M, Escartin P, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterol. 2006 Aug;131(2):451–60. [Erratum appears in Gastroenterology. 2006 Oct;131(4):1363] [PubMed: 16890599]
40.: Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2007 Jul 12;357(2):124–34. [PubMed: 17625124]
41.: von Wagner M, Huber M, Berg T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterol. 2005 Aug;129(2):522–7. [PubMed: 16083709]
42.: Yu M-L, Dai C-Y, Lin Z-Y, et al. A randomized trial of 24- vs. 48-week courses of PEG interferon alpha-2b plus ribavirin for genotype-1b-infected chronic hepatitis C patients: a pilot study in Taiwan. Liver Int. 2006 Feb;26(1):73–81. [PubMed: 16420512]
43.: Yu M-L, Dai C-Y, Huang J-F, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut. 2007 Apr;56(4):553–9. [PMC free article: PMC1856839] [PubMed: 16956917]
44.: Yu M-L, Dai C-Y, Huang J-F, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology. 2008 Jun;47(6):1884–93. [PubMed: 18508296]
45.: Zeuzem S, Diago M, Gane E, et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterol. 2004 Dec;127(6):1724–32. [PubMed: 15578510]
46.: Bronowicki J-P, Ouzan D, Asselah T, et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterol. 2006 Oct;131(4):1040–8. [PubMed: 17030174]
47.: Abergel A, Hezode C, Leroy V, et al. Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b. J Viral Hepat. 2006 Dec;13(12):811–20. [PubMed: 17109680]
48.: Brady DE, Torres DM, An JW, et al. Induction pegylated interferon alfa-2b in combination with ribavirin in patients with genotypes 1 and 4 chronic hepatitis C: a prospective, randomized, multicenter, open-label study. Clin Gastroenterol Hepatol. 2010 Jan;8(1):66–71.e1. [PubMed: 19747986]
49.: Ferenci P, Brunner H, Laferl H, et al. A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3. Hepatology. 2008 Jun;47(6):1816–23. [PubMed: 18454510]
50.: Fried MW, Jensen DM, Rodriguez-Torres M, et al. Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin. Hepatology. 2008 Oct;48(4):1033–43. [PubMed: 18697207]
51.: Helbling B, Jochum W, Stamenic I, et al. HCV-related advanced fibrosis/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin. J Viral Hepat. 2006 Nov;13(11):762–9. [PubMed: 17052276]
52.: Jacobson IM, Brown RS Jr, Freilich B, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology. 2007 Oct;46(4):971–81. [PubMed: 17894303]
53.: Jacobson IM, Brown RS Jr, McCone J, et al. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Hepatology. 2007 Oct;46(4):982–90. [PubMed: 17894323]
54.: Kawaoka T, Kawakami Y, Tsuji K, et al. Dose comparison study of pegylated interferon-alpha-2b plus ribavirin in naive Japanese patients with hepatitis C virus genotype 2: a randomized clinical trial. J Gastroenterol Hepatol. 2009 Mar;24(3):366–71. [PubMed: 19032459]
55.: Krawitt EL, Gordon SR, Grace ND, et al. A study of low dose peginterferon alpha-2b with ribavirin for the initial treatment of chronic hepatitis C. Am J Gastroenterol. 2006 Jun;101(6):1268–73. [PubMed: 16771948]
56.: Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958–65. [PubMed: 11583749]
57.: Meyer-Wyss B, Rich P, Egger H, et al. Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naive patients with chronic hepatitis C and up to moderate fibrosis. J Viral Hepat. 2006 Jul;13(7):457–65. [PubMed: 16792539]
58.: Mimidis K, Papadopoulos VP, Elefsiniotis I, et al. Hepatitis C virus survival curve analysis in naive patients treated with peginterferon alpha-2b plus ribavirin. A randomized controlled trial for induction with high doses of peginterferon and predictability of sustained viral response from early virologic data. J Gastrointestin Liver Dis. 2006 Sep;15(3):213–9. [PubMed: 17013444]
59.: Reddy KR, Shiffman ML, Rodriguez-Torres M, et al. Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads. Gastroenterol. 2010 Dec;139(6):1972–83. [PubMed: 20816836]
60.: Roberts SK, Weltman MD, Crawford DHG, et al. Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial. Hepatology. 2009 Oct;50(4):1045–55. [PubMed: 19676125]
61.: Sood A, Midha V, Hissar S, et al. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience. J Gastroenterol Hepatol. 2008 Feb;23(2):203–7. [PubMed: 17645472]
62.: McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009 Aug 6;361(6):580–93. [Erratum appears in N Engl J Med. 2009 Sep 3;361(10):1027] [PubMed: 19625712]
63.: Arase Y, Ikeda K, Suzuki F, et al. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C. Intervirology. 2007;50(1):16–23. [PubMed: 17164553]
64.: Backus LI, Boothroyd DB, Phillips BR, et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011;9:509–16. [PubMed: 21397729]
65.: Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology. 2007 Mar;45(3):579–87. [PubMed: 17326216]
66.: Cardoso A-C, Moucari R, Figueiredo-Mendes C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol. 2010 May;52(5):652–7. [PubMed: 20346533]
67.: Coverdale SA, Khan MH, Byth K, et al. Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up study. Am J Gastroenterol. 2004 Apr;99(4):636–44. [PubMed: 15089895]
68.: El Braks RE, Ganne-Carrie N, Fontaine H, et al. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J Gastroenterol. 2007;13(42):5648–53. [PMC free article: PMC4172746] [PubMed: 17948941]
69.: Fernández-Rodríguez CM, Alonso S, Martinez SM, et al. Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: Outcomes and factors predicting response. Am J Gastroenterol. 2010 [PubMed: 20700116]
70.: Hasegawa E, Kobayashi M, Kawamura Y, et al. Efficacy and anticarcinogenic activity of interferon for hepatitis C virus-related compensated cirrhosis in patients with genotype 1b low viral load or genotype 2. Hepatol Res. 2007;37(10):793–800. [PubMed: 17593231]
71.: Hung CH, Lee CM, Lu SN, et al. Long-term effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. J Viral Hepat. 2006;13(6):409–14. [PubMed: 16842444]
72.: Imazeki F, Yokosuka O, Fukai K, et al. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. Hepatology. 2003 Aug;38(2):493–502. [PubMed: 12883494]
73.: Innes HA, Hutchinson SJ, Allen S, et al. Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care. Hepatology. 2011;54(5):1547–58. [PubMed: 22045672]
74.: Izumi N, Yasuhiro A, Kurosaki M, et al. Development of hepatocellular carcinoma after interferon therapy in chronic hepatitis C. Is it possible to reduce the incidence by ribanirin and IFN combination therapy? Intervirology. 2005;48(1):59–63. [PubMed: 15785091]
75.: Kasahara A, Tanaka H, Okanoue T, et al. Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death. J Viral Hepat. 2004 Mar;11(2):148–56. [PubMed: 14996350]
76.: Maruoka D, Imazeki F, Arai M, et al. Long-term cohort study of chronic hepatitis C according to interferon efficacy. J Gastroenterol Hepatol. 2012;27(2):291–9. [PubMed: 21793911]
77.: Morgan TR, Ghany MG, Kim H-Y, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010 Sep;52(3):833–44. [PMC free article: PMC2932862] [PubMed: 20564351]
78.: Shiratori Y, Ito Y, Yokosuka O, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med. 2005 Jan 18;142(2):105–14. [PubMed: 15657158]
79.: Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147(10):677–84. [PubMed: 18025443]
80.: Yoshida H, Arakawa Y, Sata M, et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterol. 2002 Aug;123(2):483–91. [PubMed: 12145802]
81.: Yu M-L, Lin S-M, Chuang W-L, et al. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antiver Ther. 2006;11(8):985–94. [PubMed: 17302368]
82.: Arora S, O'Brien C, Zeuzem S, et al. Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life. J Gastroenterol Hepatol. 2006 Feb;21(2):406–12. [PubMed: 16509866]
83.: Bernstein D, Kleinman L, Barker CM, et al. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology. 2002 Mar;35(3):704–8. [PubMed: 11870387]
84.: Bini EJ, Mehandru S. Sustained virological response rates and health-related quality of life after interferon and ribavirin therapy in patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels. Aliment Pharmacol Ther. 2006;23(6):777–85. [PubMed: 16556180]
85.: Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology. 1999;29(1):264–70. [PubMed: 9862876]
86.: Hassanein T, Cooksley G, Sulkowski M, et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol. 2004 Apr;40(4):675–81. [PubMed: 15030985]
87.: McHutchison J, Manns M, Harvey J, et al. Adherence to therapy enhanges sustained response in chronic hepatitis C patients receiving PEG-Interferon alfa-2b plus Ribavirin [abstract] J Hepatol. 2001;34(1):2–3.
88.: Neary MP, Cort S, Bayliss MS, et al. Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients. Semin Liver Dis. 1999;19(Suppl 1):77–85. [PubMed: 10349695]
89.: Rasenack J, Zeuzem S, Feinman SV, et al. Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C. Pharmacoeconomics. 2003;21(5):341–9. [Erratum appears in Pharmacoeconomics. 2003;21(17):1290] [PubMed: 12627987]
90.: Ware JE, Bayliss MS, Mannocchia M, et al. Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group. Hepatology. 1999;30(2):550–5. [PubMed: 10421667]

Bookshelf ID: NBK115335

Contents

< PrevNext >